Medtech giant Medtronic and Johnson & Johnson subsidiary Biosense Webster are to collaborate on exploring new technologies for better diagnosing and treating patients with cardiac arrhythmias. The companies said they intend to combine Biosense's know-how in cardiac imaging and navigation with Medtronic's expertise in cardiac monitoring and diagnostics to create a new care protocol for identifying patients most likely to have a successful ablation treatment. The firms will also integrate their respective technologies to develop new therapies for complex cardiac arrhythmias under a joint R&D programme.
In addition, the two companies will work on educational initiatives aimed at electrophysiologists and healthcare professionals within the arrhythmias field.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?